Sensei Biotherapeutics, Inc. (SNSE)

Sensei Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	9.99	13.01	17.8	7.16	16.6
Short-Term Investments	31.34	52.75	89.32	140.46	-
Cash & Short-Term Investments	41.34	65.76	107.12	147.62	16.6
Cash Growth	-37.14%	-38.61%	-27.44%	789.50%	6511.95%
Prepaid Expenses	0.47	1.17	1.13	0.55	1.38
Other Current Assets	0.12	0.33	0.34	0.37	2.11
Total Current Assets	41.93	67.25	108.59	148.54	20.08
Property, Plant & Equipment	3.38	7.04	9.72	4.64	1.27
Other Long-Term Assets	0.05	0.09	0.06	0.04	0.09
Total Assets	45.36	74.37	118.38	153.23	21.43
Accounts Payable	1.25	1.69	4.47	2.46	3.88
Accrued Expenses	1.88	1.51	2.46	1.75	0.92
Current Portion of Leases	2.32	2.44	2.13	0.68	0.03
Total Current Liabilities	5.45	5.64	9.07	4.89	4.83
Long-Term Debt	-	-	-	-	0.57
Long-Term Leases	1.53	3.77	5.9	1.67	0.09
Other Long-Term Liabilities	-	0.07	-	0.15	0.05
Total Liabilities	6.98	9.48	14.97	6.71	5.54
Common Stock	0	0	0	0	-
Additional Paid-In Capital	300.45	297	302.2	296.05	55.97
Retained Earnings	-262.05	-231.9	-197.79	-149.21	-112.41
Comprehensive Income & Other	-0.01	-0.21	-1	-0.33	-
Total Common Equity	38.39	64.9	103.41	146.51	-56.44
Shareholders' Equity	38.39	64.9	103.41	146.51	15.89
Total Liabilities & Equity	45.36	74.37	118.38	153.23	21.43
Total Debt	3.85	6.21	8.03	2.35	0.69
Net Cash (Debt)	37.49	59.55	99.08	145.27	15.91
Net Cash Growth	-37.04%	-39.90%	-31.79%	813.00%	-
Net Cash Per Share	1.49	2.13	3.23	5.24	9.87
Filing Date Shares Outstanding	25.18	25.07	30.97	30.68	30.59
Total Common Shares Outstanding	25.18	25.03	30.76	30.61	1.88
Working Capital	36.48	61.61	99.52	143.65	15.25
Book Value Per Share	1.52	2.59	3.36	4.79	-30.10
Tangible Book Value	38.39	64.9	103.41	146.51	-56.44
Tangible Book Value Per Share	1.52	2.59	3.36	4.79	-30.10
Machinery	-	2.64	3.24	5.58	1.86
Leasehold Improvements	-	0.25	0.25	0.25	-

Updated Mar 28, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q